3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
NET
1
Endocrine
1
Dermatologic
1
Conditions
Neoplasms
6
Neoplasm Metastasis
5
Neoplasms, Second Primary
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Adenocarcinoma
1
Interventions
Paclitaxel
9
Carboplatin
9
pembrolizumab
7
Radiotherapy
7
Cisplatin
5
Axitinib
4
Pemetrexed
3
Nivolumab
3
trifluridine tipiracil drug combination
2
regorafenib
2
osimertinib
2
fludarabine
2
dacomitinib
2
catumaxomab
2
Trastuzumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Nurses
2
Interleukin-2
2
Gemcitabine
2
Docetaxel
2
Cyclophosphamide
2
Cetuximab
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vatalanib
1
temsirolimus
1
sovateltide
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
avelumab
×
Tumor-Agnostic
×
Clear all
NCT04698213
2021-01-06
TIDE-A
Consorzio Oncotech
Phase 2
Unknown
75 enrolled